Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|September 28, 2020

Stress Reactions to COVID-19

Author(s)Victor Schwartz, MD

This video examines the differences between typical, non-pathological reactions to the stress induced by the COVID-19 pandemic and psychopathology (or mental illness).

The clinical and policy ramifications of this confusion of categories is also explored in addition to explaining the value and importance of affirming the real-even if painful-emotional experiences of those impacted by the pandemic.

Dr Schwartz is Clinical Associate Professor of Psychiatry, NYU School of Medicine and CEO of Mind Strategies.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

long covid

Phase 2 Trial of Bezisterim for Neurological Symptoms of Long COVID: Treatment Phase Completed

August 31st 2026

1 expert is featured in this series.

Take-Home Messages: Clinical Confidence in Transitioning Patients to Cobenfy

ByDavid Walling, PhD

July 8th 2026

1 expert is featured in this series.

Managing Tolerability and Setting Patients Up for Success with Cobenfy

ByDavid Walling, PhD

July 1st 2026

1 expert is featured in this series.

The Switch Study: Why a New Mechanism Demands a New Approach

ByDavid Walling, PhD

June 17th 2026

dewboreas/Adobe Stock

Student Researchers Share Projects on Alzheimer Disease, Autism, and Long COVID, From the Regeneron Science Talent Search

ByJessica Walters,Jashvi Desai,Edward Kang,Leon Wang

April 21st 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

Vol 43, Issue 9 - Interactive

FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval

Insights on the New Adult ADHD Guidelines: A Conversation With the President of APSARD

Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Phase 2 Failure: JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder